Transcatheter Technologies GmbH Closes €2.6 million ‘Series B’ Funding Round

Clinical Trials for the TRINITY transcatheter aortic valve to begin this year

Transcatheter Technologies GmbH, the transcatheter heart valve company that is developing the TRINITY fully repositionable device for transcatheter aortic valve implantation, announced today that it has closed its € 2.6 million ‘Series B’ funding round.

Existing investors and undisclosed new investors participated in this funding round, which will be used to enter clinical trials. Rolf Käse, PhD, lead investor (Tubaflex Beteiligungs GmbH) and chairman of the advisory board, stated that, “We are proud to be part of this determined and creative team, and we are very confident that we will see the First in Human implantation later this year.”

“We are delighted about this substantial investment by a strong syndicate of highly experienced Medtech/Biotech investors. The new investment round is another step for Transcatheter Technologies GmbH toward the first clinical implantation,” said Dr. Wolfgang Goetz, CEO. Hou-Sen Lim, CTO , added “While preclinical validation of TRINITY proved the excellent performance of our aortic valve prosthesis, we now anticipate its full clinical application.”

Clinicians who commented on the TRINITY system included Prof. Dr. Thomas Walther, Director of Cardiac Surgery at the Kerckhoff Clinic in Bad Nauheim, Germany, who said, “Having proven safe implantation and complete repositioning of TRINITY in the experimental model, the device offers promising perspectives for clinical practice in the future.” Additionally, Prof. Dr. Christian Hengstenberg, Vice Director of the Cardiology Dept. at the German Heart Center in Munich, Germany added, “I am thrilled with the TRINITY valve system. Congratulations to the entire team! This is a real innovation on the valve market and a very big improvement to the existing TAVI systems.”

About Transcatheter Technologies GmbH
Transcatheter Technologies GmbH, incorporated in 2009, is a privately held company located in Regensburg, Germany. It is currently developing TRINITY, a proprietary system for transcatheter aortic valve implantation. The TRINITY transcatheter aortic heart valve prosthesis and implantation system combine a novel anchoring mechanism with a unique delivery catheter to enable the valve prosthesis to be accurately and precisely positioned. After full evaluation of valve prosthesis function, TRINITY can be repositioned without foreshortening of the valve prosthesis frame. The TRINITY valve is pre-mounted on a detachable tip to simplify the assembly of the catheter system in the operating room.
www.transcatheter-technologies.com

Contact:
Wolfgang Goetz, MD, PhD, CEO
Transcatheter Technologies GmbH
BioPark Regensburg
Josef-Engert-Str. 11
93053 Regensburg
Germany
phone: +49 170-630-9920
w.g@transcatheter-technologies.com

About High-Tech Gruenderfonds
High-Tech Gruenderfonds invests in young, high potential high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping and to market launch. Typically, High-Tech Gruenderfonds invests EUR 500,000 in the seed stage, with the potential for up to a total of EUR 2 million per portfolio company in follow-on financing. Investors in this public/private partnership include the Federal Ministry of Economics and Technology, the KfW Banking Group, as well as strategic corporate investors including ALTANA, BASF, B. Braun, Robert Bosch, CEWE Color, Daimler, Deutsche Post DHL, Deutsche Telekom, Evonik, Lanxess, media + more venture Beteiligungs GmbH & Co. KG, METRO, Qiagen, RWE Innogy, SAP, Tengelmann and Carl Zeiss. High-Tech Gruenderfonds has about EUR 573.5 million under management in two funds (EUR 272 million HTGF I, EUR 301.5 million HTGF II).

Contact:
Stefanie Zillikens
Marketing & Communications Manager
High-Tech Gründerfonds Management GmbH
Schlegelstraße 2
53113 Bonn
phone: + 49 228 823001-07
s.zillikens@high-tech-gruenderfonds.de
www.high-tech-gruenderfonds.de